All symptomatic Alzheimer's patients and one-third of cognitively intact persons over age 65 have biomarker evidence of cerebral amyloidosis. One presumes, therefore, that stimulating amyloid clearance would help maximize the therapeutic reduction of neuropathology to prevent or arrest neurodegeneration and cognitive failure. Autosomal-dominant familial Alzheimer's disease (FAD) is rare and is attributable to misprocessing of the amyloid precursor protein (APP) to generate excessive or mutant hyperaggregable Ab42 which, in turn, serves as a ''seed'' for initiation of Ab fibrillogenesis and oligomerization in the brain interstitium. Some Ab assembly states are believed to be especially responsible for progression to neurofibrillary tangle formation and neurodegeneration. While research on potential AD treatments has focused on many important discoveries centered around mutations linked with FAD, in most people, no mutations exist that enable perfect prediction on an individual basis of those destined to develop more common sporadic forms of AD (for review, see Gandy and DeKosky, 2013) .
Nonneuronal CNS cells such as microglia, the brain's intrinsic phagocytes, are beginning to take center stage as we advance our understanding of the molecular pathogenesis of common, late onset, sporadic AD. Several new papers, including one by Griciuc et al. in this issue of Neuron, shift the focus of AD research to the (patho)physiological role of microglia in AD. Griciuc et al. (2013) show that the microglial molecule CD33, an immunoglobulin-like cell-surface protein, inhibits Ab clearance in cell culture and in transgenic mouse brain. CD33 has been genetically linked to AD (Naj et al., 2011) , instantly providing disease relevance to the molecule. Griciuc et al. (2013) also show that human AD brain tissue contains excess CD33, suggesting that dysregulation of CD33 plays a role in disease pathogenesis. This result may provide a molecular explanation for the Ab-mediated dysfunction of microglia evidenced by the failure of microglia to reduce Ab burden in a transgenic mouse model of AD (Krabbe et al., 2013) , ultimately resulting in microglial senescence (Miller and Streit, 2007) .
Wholesale ablation of microglia in AD transgenic mice (at least for a limited period of time) has no obvious effect on plaque burden, arguing against their critical importance in disease pathogenesis (Grathwohl et al., 2009) . While this study was limited by the model-dependent inability to assess the consequences of microglia ablation on AD pathology for a prolonged period or to differentiate effects of various pathogenic Ab species, Grathwohl et al. (2009) fuelled further investigations on the role(s) of microglia on AD pathology. Recent papers show that inhibition of interleukins 12 and 23 (Vom Berg et al., 2012) or genetic deficiency of NALP3, a component of the inflammasome (Heneka et al., 2013) led to a substantial reduction of AD pathology illustrating how microglia take on multiple, distinct roles during the course of AD. Another recent discovery also links microglia to AD via the molecule CR1. Loss of CR1 modulates the impact of the apolipoprotein E ε4 (APOE ε4) allele on brain fibrillar amyloid burden and indicates that microglial dysfunction can be genetically linked to AD (Thambisetty et al., 2013) . Surprisingly, those patients with a risky CR1 genotype and an APOE ε4 allele have an increased risk for Alzheimer's, yet their fibrillar amyloid burden is reduced in comparison to the APOE ε4 subjects that lack the risky allele. Therefore, although the molecular explanation for CR1-associated AD remains to be revealed, these studies suggest that microglia may be helpful or harmful, either alternately or even simultaneously. After migrating through the interstitial space of the brain to reach a nascent Ab deposit, the balance between beneficial versus harmful effects is unpredictable and may vary according to individual factors. The most straightforward model is that microglia are beneficial when they keep pace with Ab aggregate accumulation. Once microglia are poisoned by Ab, and/or once the Ab deposit exceeds a size that would permit its engulfment by microglia, they may now facilitate or instigate neuronal dysfunction and disease progression, evolving from rescuer to murderer. This does not exclude the possibility that Ab per se is also directly neurotoxic; the alternative pathways-namely intrinsic Ab neurotoxicity, indirect neurotoxicity of microglia in the presence of Ab and Abdriven microglial dysfunction-are not mutually exclusive but may rather act in concert to exacerbate AD pathology.
As a result of this revelation, it is clear that interference with microglial function could be beneficial, harmful, or both, depending on the timing and/or duration of intervention. Though inhibition or ablation of microglia at late stages of AD had no obvious effect on plaque burden (Grathwohl et al., 2009 ), the situation is quite different at early time points, when microglia appear to support both clearance of AD pathology and exacerbation of Ab toxicity. This means that microglia-targeted therapies must be finely targeted, precisely timed, and carefully modulated at the molecular level. Existing drugs that could be aimed, e.g., at increasing the phagocytic activity of microglia include the peroxisome proliferatoractivated receptor g (PPARg) agonist pioglitazone and a novel selective PPARa/g modulator, DSP-8658 (Yamanaka et al., 2012) , as well as the mixed acetylcholinesterase inhibitor-nicotinic agonist galantamine (Takata et al. 2010) , which is currently used in the symptomatic treatment of AD. Moreover, there is still much to learn about microglia when precisely assessing their roles during therapeutic manipulations such as Ab immunotherapy. There will be equal interest in dissecting which effects are truly conferred by CNS resident microglia or by their myeloid counterparts entering the brain during the course of AD (an issue of intense debate in the field; e.g., Prinz et al., 2011) . Considering the prospect of potential cell-based interventional approaches, these studies should result in exciting and crucial insights.
CD33 now joins this new class of microglia-related molecules for possible evaluation in human clinical trials. Griciuc et al. (2013) establish the benefit of genetic CD33 deficiency. The assessment of drugs that safely reduce CD33 levels (e.g., anti-CD33 antibodies) is the obvious next goal. Along this line, the success reported by Vom Berg et al. (2012) takes us beyond genetic deletion and on to a concrete example of immunotherapeutic inhibition of IL-12/23, providing proof-ofprinciple evidence that relevant microglial pathways can indeed be viable therapeutic targets.
Two other recent papers link a known microglial Ab clearing molecule, TREM2, to Alzheimer's disease (Guerreiro et al., 2013; Jonsson et al., 2013) . Rounding out this collection of new and emerging AD/microglia publications is a fascinating and unconventional ''multiscale'' genetics study that implicates an AD link for TYROBP, a microglial molecule linked to both TREM2 and CD33 (Zhang et al., 2013) . Thus, the first Alzheimer's network is born, and, unlike autosomal dominant FAD, the focus of this network is on microglia (Figure 1) , not on Ab speciation or generation.
The implications of this explosion of AD/microglia papers are profound. First, the longstanding questions about whether microglia are important in AD and in Ab clearance would appear to be put to rest. Second, we have new potential therapeutic opportunities for small molecule discovery, among the first candidate targets for small molecules that might be employed to accelerate Ab clearance. Third, these AD/microglia studies describe molecules that define a new Alzheimer's network as well as the pathways that are contained therein. Zhang, Schadt, and their colleagues have suggested that such pathways and networks as linked entities might constitute complex drug ''megatargets'' and that superior AD drugs might result from a search for drugs that correct entire networks or subnetworks by acting on their hubs or ''drivers'' (Zhang et al., 2013) . Lastly, the novel multiscale analysis of Zhang et al. (2013) , heretofore untested in AD, has been instantly validated by virtue of its inclusion of two microglial genes, CD33 and TREM2, linked to AD by more conventional genetic approaches.
Undoubtedly, this eruption of AD/microglial genes will stimulate new interest in these cells and pathways. ''The more, the merrier'' always applies in the case of drug targets, and this CD33-TREM2-TYROBP network and its component pathways as well as IL-12/23 signaling molecules, represent true groundbreaking progress. The pathways defined by these molecules are the first clues based on human disease genetics since the cloning of presenilin 1 in 1995, and the first clues ever to emerge solely from studies of common forms of late onset, sporadic AD. The implication is that Zhang et al. (2013) may point the way to new drug discovery efforts in AD as has already been true in peripheral inflammatory diseases. A new iteration of multiscale analysis focusing on early stage AD is underway, as is whole exome sequencing of the DNA from 50 patients with common, late onset, sporadic AD. One would predict that, in both of these gene hunts, microglial molecules-mere bit players just 6 months ago-may emerge as marquee stars in the pathogenesis of AD wherein they serve as essential, dynamic, and Janus-like components of the amyloid hypothesis. In this issue of Neuron, Yin et al. (2013) demonstrate that overexpression of Neuregulin 1 causes synaptic dysfunction and schizophrenia-like behavioral deficits. These abnormalities can be reverted by restoring normal levels of Neuregulin 1, opening possibilities for the treatment of mental disease.
Schizophrenia is a severe mental illness that affects approximately 1% of the population worldwide. Genetic factors play a major role in the etiology of schizophrenia, with an estimated heritability of around 80%. Genetic variation in Neuregulin 1 (NRG1) has been repeatedly linked to the disorder in multiple human populations. In particular, more than 80 single nucleotide polymorphisms localized in noncoding regions of this gene have been identified (Mei and Xiong, 2008) . These observations led to the hypothesis that expression of NRG1 might be altered in schizophrenia.
Alternative splicing of NRG1 generates more than 30 isoforms classified in six different types (I to VI) depending on their structure (Mei and Xiong, 2008) . They all share an epidermal growth factor (EGF)-like domain, which is required for the activation of several members of the ErbB family of receptor tyrosine kinases. In schizophrenia, the expression of particular isoforms of NRG1 seems altered, although reports are contradictory. For example, several studies reported a reduction in the levels of the isoform 1 alpha of NRG1 in the brain of schizophrenia patients (e.g., Bertram et al., 2007) , while others showed elevated levels of NRG1 in a particular risk haplotype (e.g., Weickert et al., 2012) . Consistent with this later view, several other studies have shown increased NRG1 mRNA and protein levels in the hippocampus and prefrontal cortex of schizophrenia patients (Hashimoto et al., 2004; Petryshen et al., 2005) . These contradictory findings have been surprisingly replicated in mice: both loss and gain of NRG1
